Institutions / Persistent Asset Partners Ltd / Activity
Activity — Persistent Asset Partners Ltd
94 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2026 as of | Add | Robinhood Markets, Inc. Common stock | $18.50M | +184K +2787.07% | 191,095 6.05% of portfolio | medium |
| Q2 2026 as of | Add | United Therapeutics Corp Common stock | $5.81M | +11K +327.95% | 13,981 2.39% of portfolio | medium |
| Q4 2025 as of | Add | Elevance Health Inc Common stock | $5.34M | +15K +195.14% | 23,039 2.55% of portfolio | medium |
| Q4 2025 as of | Add | Intel Corp Common stock | $4.16M | +113K +352.63% | 144,840 1.69% of portfolio | low |
| Q2 2026 as of | Add | Revolution Medicines, Inc. Common stock | $3.97M | +21K +120.82% | 38,726 2.29% of portfolio | low |
| Q2 2026 as of | Add | Intel Corp Common stock | $3.95M | +28K +19.52% | 173,113 7.63% of portfolio | low |
| Q2 2026 as of | Add | Cogent Biosciences, Inc. Common stock | $3.51M | +91K +191.11% | 138,272 1.69% of portfolio | low |
| Q2 2026 as of | Add | 00370M103 Common stock | $2.64M | +20K +81.28% | 44,256 1.86% of portfolio | low |
| Q2 2026 as of | Add | Lam Research Corp Common stock | $2.50M | +6K +188.27% | 8,824 1.21% of portfolio | low |
| Q4 2025 as of | Add | 00370M103 Common stock | $2.34M | +15K +154.20% | 24,413 1.22% of portfolio | low |
| Q2 2026 as of | Add | BioMarin Pharmaceutical Inc Common stock | $2.33M | +41K +104.25% | 79,933 1.44% of portfolio | low |
| Q2 2026 as of | Add | Edgewise Therapeutics, Inc. Common stock | $1.96M | +48K +227.49% | 69,441 0.89% of portfolio | low |
| Q4 2025 as of | Add | Viking Therapeutics Inc Common stock | $1.62M | +46K +103.05% | 90,514 1.00% of portfolio | low |
| Q4 2025 as of | Add | Terns Pharmaceuticals, Inc. Common stock | $1.58M | +39K +52.70% | 113,555 1.45% of portfolio | low |
| Q4 2025 as of | Add | Bancorp Inc/The Common stock | $1.25M | +18K +270.42% | 25,259 0.54% of portfolio | low |
| Q2 2026 as of | Add | IMCR Immunocore Holdings Plc-Adr ADR | $1.18M | +37K +133.47% | 65,214 0.65% of portfolio | low |
| Q2 2026 as of | Add | Corning Inc /Ny Common stock | $1.05M | +4K +77.56% | 9,368 0.75% of portfolio | low |
| Q2 2026 as of | Add | PDD PDD Holdings Inc. ADR | $894.2K | +12K +71.38% | 28,145 0.68% of portfolio | low |
| Q4 2025 as of | Add | Cogent Biosciences, Inc. Common stock | $888.5K | +25K +111.24% | 47,499 0.53% of portfolio | low |
| Q4 2025 as of | Add | NVIDIA Corp Common stock | $881.8K | +5K +40.71% | 16,342 0.96% of portfolio | low |
| Q2 2026 as of | Add | Viking Therapeutics Inc Common stock | $866.9K | +22K +24.55% | 112,736 1.39% of portfolio | low |
| Q2 2026 as of | Add | TripAdvisor, Inc. Common stock | $801.4K | +58K +58.46% | 158,456 0.69% of portfolio | low |
| Q2 2026 as of | Add | EXPAND ENERGY Corp Common stock | $769.1K | +9K +104.27% | 17,175 0.48% of portfolio | low |
| Q2 2026 as of | Add | Zymeworks Inc. Common stock | $747.3K | +29K +389.18% | 35,935 0.30% of portfolio | low |
| Q4 2025 as of | Add | Coastal Financial Corp Common stock | $727.1K | +6K +69.79% | 15,436 0.56% of portfolio | low |
| Q4 2025 as of | Add | Synopsys Inc Common stock | $684.4K | +1K +112.25% | 2,755 0.41% of portfolio | low |
| Q2 2026 as of | Add | G89479102 Common stock | $681.4K | +26K +87.38% | 56,215 0.46% of portfolio | low |
| Q4 2025 as of | Add | BrightSpring Health Services, Inc. Common stock | $668.0K | +18K +23.45% | 93,897 1.11% of portfolio | low |
| Q2 2026 as of | Add | CRBP Corbus Pharmaceuticals Holdings, Inc. Common Stock | $659.7K | +70K +1067.74% | 76,919 0.23% of portfolio | low |
| Q4 2025 as of | Add | Bank of America Corp /De Common stock | $657.7K | +12K +131.55% | 21,050 0.37% of portfolio | low |
| Q2 2026 as of | Add | First Solar Inc Common stock | $610.5K | +3K +666.67% | 3,013 0.22% of portfolio | low |
| Q2 2026 as of | Add | B38564108 Common stock | $594.5K | +42K +76.60% | 97,131 0.43% of portfolio | low |
| Q2 2026 as of | Add | Spyre Therapeutics, Inc. Common stock | $578.3K | +7K +290.03% | 8,760 0.25% of portfolio | low |
| Q4 2025 as of | Add | TG Therapeutics Inc Common stock | $571.5K | +19K +136.54% | 33,212 0.31% of portfolio | low |
| Q2 2026 as of | Add | Vaxcyte, Inc. Common stock | $568.0K | +10K +183.18% | 15,105 0.28% of portfolio | low |
| Q4 2025 as of | Add | Ani Pharmaceuticals Inc Common stock | $561.4K | +7K +98.67% | 14,320 0.36% of portfolio | low |
| Q2 2026 as of | Add | 284902509 Common stock | $520.9K | +17K +33.29% | 67,090 0.66% of portfolio | low |
| Q2 2026 as of | Add | Stryker Corp Common stock | $435.1K | +1K +257.84% | 1,918 0.19% of portfolio | low |
| Q4 2025 as of | Add | Enhabit, Inc. Common stock | $389.2K | +42K +22.74% | 227,806 0.66% of portfolio | low |
| Q2 2026 as of | Add | Thermo Fisher Scientific Inc. Common stock | $388.6K | +775 +168.48% | 1,235 0.20% of portfolio | low |
| Q2 2026 as of | Add | PHAT Phathom Pharmaceuticals, Inc. Common Stock | $377.0K | +35K +269.02% | 47,663 0.16% of portfolio | low |
| Q2 2026 as of | Add | Viridian Therapeutics, Inc. Common stock | $364.1K | +20K +349.56% | 25,490 0.15% of portfolio | low |
| Q2 2026 as of | Add | N71542109 Common stock | $355.8K | +191K +423.66% | 236,454 0.14% of portfolio | low |
| Q4 2025 as of | Add | 876511106 Common stock | $338.9K | +60K +30.17% | 258,329 0.46% of portfolio | low |
| Q4 2025 as of | Add | Ventyx Biosciences, Inc. Common stock | $337.2K | +37K +229.19% | 53,642 0.15% of portfolio | low |
| Q4 2025 as of | Add | Trevi Therapeutics, Inc. Common stock | $327.3K | +26K +132.78% | 45,830 0.18% of portfolio | low |
| Q2 2026 as of | Add | Contineum Therapeutics, Inc. Common stock | $314.4K | +19K +138.48% | 33,037 0.17% of portfolio | low |
| Q2 2026 as of | Add | Sanofi Common stock | $311.6K | +7K +98.12% | 14,750 0.20% of portfolio | low |
| Q4 2025 as of | Add | Revolution Medicines, Inc. Common stock | $311.4K | +4K +28.69% | 17,537 0.44% of portfolio | low |
| Q2 2026 as of | Add | 46124U107 Common stock | $300.4K | +79K +61.27% | 209,182 0.25% of portfolio | low |